(VIANEWS) – DexCom (DXCM), Cigna (CI), Hercules Technology Growth Capital (HTGC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. DexCom (DXCM)
27.5% sales growth and 18.42% return on equity
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, DexCom has a trailing twelve months EPS of $0.91.
PE Ratio
DexCom has a trailing twelve months price to earnings ratio of 130.7. Meaning, the purchaser of the share is investing $130.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.42%.
Previous days news about DexCom(DXCM)
- According to Zacks on Monday, 4 December, "Some better-ranked stocks in the broader medical space are Haemonetics (HAE Quick QuoteHAE – Free Report) , Insulet (PODD Quick QuotePODD – Free Report) and DexCom (DXCM Quick QuoteDXCM – Free Report) . ", "Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). "
- According to Zacks on Monday, 4 December, "While Integer sports a Zacks Rank #1 (Strong Buy), DexCom and Medpace carry a Zacks Rank #2 (Buy) at present. "
- According to Zacks on Tuesday, 5 December, "Some better-ranked stocks in the broader medical space are Haemonetics (HAE Quick QuoteHAE – Free Report) , DexCom (DXCM Quick QuoteDXCM – Free Report) and Insulet (PODD Quick QuotePODD – Free Report) . ", "Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). "
- According to Zacks on Tuesday, 5 December, "Some better-ranked stocks in the broader medical space are Haemonetics (HAE Quick QuoteHAE – Free Report) , Insulet (PODD Quick QuotePODD – Free Report) and DexCom (DXCM Quick QuoteDXCM – Free Report) . ", "Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). "
2. Cigna (CI)
19.3% sales growth and 11.99% return on equity
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. The company also offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. It distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Earnings Per Share
As for profitability, Cigna has a trailing twelve months EPS of $17.74.
PE Ratio
Cigna has a trailing twelve months price to earnings ratio of 14.44. Meaning, the purchaser of the share is investing $14.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.99%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.5%, now sitting on 189.86B for the twelve trailing months.
Previous days news about Cigna(CI)
- According to MarketWatch on Tuesday, 5 December, "Zepbound, , and will be added to Cigna Healthcare commercial formularies as of Dec. 15, Lilly said. "
3. Hercules Technology Growth Capital (HTGC)
17% sales growth and 18.57% return on equity
Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. The firm prefers to invest between $10 million to $250 million in equity per transactions. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in December 2003 and is based in Palo Alto, California with additional offices in Connecticut; Boston, Massachusetts; San Diego, California; Westport, Connecticut; Elmhurst, Illinois; Santa Monica, California; McLean, Virginia; New York, New York; Radnor, Pennsylvania; and Washington, District of Columbia and London, United Kingdom.
Earnings Per Share
As for profitability, Hercules Technology Growth Capital has a trailing twelve months EPS of $2.
PE Ratio
Hercules Technology Growth Capital has a trailing twelve months price to earnings ratio of 7.7. Meaning, the purchaser of the share is investing $7.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.57%.
4. Ford (F)
16.2% sales growth and 14.15% return on equity
Ford Motor Company develops, delivers, and services a range of Ford trucks, commercial cars and vans, sport utility vehicles, and Lincoln luxury vehicles worldwide. It operates through Ford Blue, Ford Model e, and Ford Pro; Ford Next; and Ford Credit segments. The company sells Ford and Lincoln vehicles, service parts, and accessories through distributors and dealers, as well as through dealerships to commercial fleet customers, daily rental car companies, and governments. It also engages in vehicle-related financing and leasing activities to and through automotive dealers. In addition, the company provides retail installment sale contracts for new and used vehicles; and direct financing leases for new vehicles to retail and commercial customers, such as leasing companies, government entities, daily rental companies, and fleet customers. Further, it offers wholesale loans to dealers to finance the purchase of vehicle inventory; and loans to dealers to finance working capital and enhance dealership facilities, purchase dealership real estate, and other dealer vehicle programs. The company was incorporated in 1903 and is based in Dearborn, Michigan.
Earnings Per Share
As for profitability, Ford has a trailing twelve months EPS of $1.53.
PE Ratio
Ford has a trailing twelve months price to earnings ratio of 7.05. Meaning, the purchaser of the share is investing $7.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.15%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Oct 30, 2023, the estimated forward annual dividend rate is 0.6 and the estimated forward annual dividend yield is 5.67%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 72.5% and a negative 23.8%, respectively.
Moving Average
Ford’s value is below its 50-day moving average of $11.09 and way below its 200-day moving average of $12.29.
5. Carrols Restaurant Group (TAST)
7.9% sales growth and 5.3% return on equity
Carrols Restaurant Group, Inc., through its subsidiaries, operates as a restaurant company in the United States. The company operates as a Burger King franchisee. As of January 3, 2021, it operated 1,009 Burger King restaurants located in 23 Northeastern, Midwestern, Southcentral, and Southeastern states; and 65 Popeyes restaurants in seven Southeastern states. The company was founded in 1960 and is headquartered in Syracuse, New York.
Earnings Per Share
As for profitability, Carrols Restaurant Group has a trailing twelve months EPS of $0.06.
PE Ratio
Carrols Restaurant Group has a trailing twelve months price to earnings ratio of 126.17. Meaning, the purchaser of the share is investing $126.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.3%.
Sales Growth
Carrols Restaurant Group’s sales growth is 4.6% for the ongoing quarter and 7.9% for the next.
6. Marriott International (MAR)
7.6% sales growth and 1446.77% return on equity
Marriott International, Inc. operates, franchises, and licenses hotel, residential, timeshare, and other lodging properties worldwide. The company operates through U.S. and Canada, and International segments. It operates its properties under the JW Marriott, The Ritz-Carlton, Ritz-Carlton Reserve, W Hotels, The Luxury Collection, St. Regis, EDITION, Bvlgari, Renaissance, Le Méridien, Marriott, Sheraton, Westin, Four Points, Delta Hotels by Marriott, Autograph Collection, Tribute Portfolio, Marriott Hotels, Marriott Executive Apartments, Marriott Vacation Club, Gaylord Hotels, Design Hotels, Courtyard, Residence Inn, Fairfield, SpringHill Suites, TownePlace Suites, Protea Hotels, Aloft Hotels, AC Hotels by Marriott, Element Hotels, and Moxy Hotels brand names. It operates properties under 30 brand names in 138 countries and territories. Marriott International, Inc. was founded in 1927 and is headquartered in Bethesda, Maryland.
Earnings Per Share
As for profitability, Marriott International has a trailing twelve months EPS of $9.43.
PE Ratio
Marriott International has a trailing twelve months price to earnings ratio of 21.78. Meaning, the purchaser of the share is investing $21.78 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1446.77%.
Sales Growth
Marriott International’s sales growth is 5% for the present quarter and 7.6% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Nov 20, 2023, the estimated forward annual dividend rate is 2.08 and the estimated forward annual dividend yield is 0.99%.
Yearly Top and Bottom Value
Marriott International’s stock is valued at $205.43 at 19:22 EST, under its 52-week high of $210.98 and way higher than its 52-week low of $145.37.
7. Gartner (IT)
6.3% sales growth and 370.99% return on equity
Gartner, Inc. operates as a research and advisory company in the United States, Canada, Europe, the Middle East, Africa, and internationally. It operates through three segments: Research, Conferences, and Consulting. The Research segment delivers its research primarily through a subscription service that include on-demand access to published research content, data and benchmarks, and direct access to a network of research experts. The Conferences segment offers business professionals in an organization the opportunity to learn, share, and network. The Consulting segment offers market research, custom analysis, and on-the-ground support services. This segment also offers actionable solutions for IT-related priorities, including IT cost optimization, digital transformation, and IT sourcing optimization. Gartner, Inc. was founded in 1979 and is headquartered in Stamford, Connecticut.
Earnings Per Share
As for profitability, Gartner has a trailing twelve months EPS of $11.61.
PE Ratio
Gartner has a trailing twelve months price to earnings ratio of 38.05. Meaning, the purchaser of the share is investing $38.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 370.99%.
Previous days news about Gartner(IT)
- The zacks analyst blog highlights cboe global markets, gartner, Intel, royal caribbean cruises and davita. According to Zacks on Tuesday, 5 December, "Stocks recently featured in the blog include: Cboe Global Markets Inc. (CBOE Quick QuoteCBOE – Free Report) , Gartner Inc. (IT Quick QuoteIT – Free Report) , Intel Corp. (INTC Quick QuoteINTC – Free Report) , Royal Caribbean Cruises Ltd. "
